Moderna announced today that mRNA-1283, its next-generation Covid-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2. compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine.

'We are delighted to announce our fourth infectious disease vaccine program with positive Phase 3 data, validating our robust mRNA platform,' said Stéphane Bancel, President and CEO of Moderna.

mRNA-1283 is an essential component of our combined COVID-19 and influenza vaccine, mRNA-1083, and this milestone gives us confidence in our ability to bring this much-needed vaccine to market', he added.

Copyright (c) 2024 CercleFinance.com. All rights reserved.